Eradication rate and histological changes after Helicobacter pylori eradication treatment in gastric cancer patients following subtotal gastrectomy
- PMID: 25852279
- PMCID: PMC4385541
- DOI: 10.3748/wjg.v21.i13.3936
Eradication rate and histological changes after Helicobacter pylori eradication treatment in gastric cancer patients following subtotal gastrectomy
Abstract
Aim: To investigate the eradication rate and histological changes after Helicobacter pylori (H. pylori) eradication treatment following subtotal gastrectomy for gastric cancer.
Methods: A total of 610 patients with H. pylori infection who had undergone surgery for either early or advanced gastric adenocarcinoma between May 2004 and December 2010 were retrospectively studied. A total of 584 patients with proven H. pylori infection after surgery for gastric cancer were enrolled in this study. Patients received a seven day standard triple regimen as first-line therapy and a 10 d bismuth-containing quadruple regimen as second-line therapy in cases of eradication failure. The patients underwent an esophagogastroduodenoscopy (EGD) between six and 12 mo after surgery, followed by annual EGDs. A further EGD was conducted 12 mo after confirming the result of the eradication and the histological changes. A gastric biopsy specimen for histological examination and Campylobacter-like organism testing was obtained from the lesser and greater curvature of the corpus of the remnant stomach. Histological changes in the gastric mucosa were assessed using the updated Sydney system before eradication therapy and at follow-up after 12 mo.
Results: Eradication rates with the first-line and second-line therapies were 78.4% (458/584) and 90% (36/40), respectively, by intention-to-treat analysis and 85.3% (458/530) and 92.3% (36/39), respectively, by per-protocol analysis. The univariate and multivariate analyses revealed that Billroth II surgery was an independent factor predictive of eradication success in the eradication success group (OR = 1.53, 95%CI: 1.41-1.65, P = 0.021). The atrophy and intestinal metaplasia (IM) scores 12 mo after eradication were significantly lower in the eradication success group than in the eradication failure group (0.25 ± 0.04 vs 0.47 ± 0.12, P = 0.023; 0.27 ± 0.04 vs 0.51 ± 0.12, P = 0.015, respectively). The atrophy and IM scores 12 mo after successful eradication were significantly lower in the Billroth II group than in the Billroth I group (0.13 ± 0.09 vs 0.31 ± 0.12, P = 0.029; 0.32 ± 0.24 vs 0.37 ± 0.13, P = 0.034, respectively).
Conclusion: Patients with H. pylori following subtotal gastrectomy had a similar eradication rate to patients with an intact stomach. H. pylori eradication is recommended after subtotal gastrectomy.
Keywords: Atrophy; Eradication; Esophagogastroduodenoscopy; Gastrectomy; Helicobacter pylori; Intestinal metaplasia.
Figures
Similar articles
-
Effect of Helicobacter pylori Eradication on Long-Term Survival after Distal Gastrectomy for Gastric Cancer.Cancer Res Treat. 2016 Jul;48(3):1020-9. doi: 10.4143/crt.2015.264. Epub 2015 Nov 17. Cancer Res Treat. 2016. PMID: 26582396 Free PMC article.
-
Randomised clinical trial: the effects of Helicobacter pylori eradication on glandular atrophy and intestinal metaplasia after subtotal gastrectomy for gastric cancer.Aliment Pharmacol Ther. 2013 Sep;38(5):477-89. doi: 10.1111/apt.12402. Epub 2013 Jul 3. Aliment Pharmacol Ther. 2013. PMID: 23822578 Clinical Trial.
-
Preoperative versus postoperative Helicobacter pylori eradication therapy in gastric cancer patients: a randomized trial.Am J Gastroenterol. 2008 Jan;103(1):48-54. doi: 10.1111/j.1572-0241.2007.01482.x. Epub 2007 Aug 21. Am J Gastroenterol. 2008. PMID: 17714557 Clinical Trial.
-
Management of Helicobacter pylori infection after gastric surgery.World J Gastroenterol. 2014 May 14;20(18):5274-82. doi: 10.3748/wjg.v20.i18.5274. World J Gastroenterol. 2014. PMID: 24833857 Free PMC article. Review.
-
[Helicobacter pylori-associated diseases].Gastroenterol Hepatol. 2015 Sep;38 Suppl 1:39-48. doi: 10.1016/S0210-5705(15)30018-2. Gastroenterol Hepatol. 2015. PMID: 26520195 Review. Spanish.
Cited by
-
Effect of Helicobacter pylori Eradication on Long-Term Survival after Distal Gastrectomy for Gastric Cancer.Cancer Res Treat. 2016 Jul;48(3):1020-9. doi: 10.4143/crt.2015.264. Epub 2015 Nov 17. Cancer Res Treat. 2016. PMID: 26582396 Free PMC article.
-
Helicobacter pylori prevalence and its spontaneous eradication rate after distal or proximal gastrectomy for gastric cancer: A multicenter prospective cohort study.Ann Gastroenterol Surg. 2024 Nov 1;9(2):244-250. doi: 10.1002/ags3.12860. eCollection 2025 Mar. Ann Gastroenterol Surg. 2024. PMID: 40046515 Free PMC article.
-
Impacts of H. pylori mixed-infection and heteroresistance on clinical outcomes.Gastroenterol Hepatol Bed Bench. 2015 Spring;8(Suppl 1):S1-5. Gastroenterol Hepatol Bed Bench. 2015. PMID: 26171132 Free PMC article. No abstract available.
-
Effect of Helicobacter pylori eradication after subtotal gastrectomy on the survival rate of patients with gastric cancer: follow-up for up to 15 years.Gastric Cancer. 2020 Nov;23(6):1051-1063. doi: 10.1007/s10120-020-01076-2. Epub 2020 May 2. Gastric Cancer. 2020. PMID: 32361784
-
Effect of Helicobacter pylori eradication on remnant stomach neoplasms after curative gastrectomy (HELP-GC): Protocol of a HELP-GC randomized controlled trial.PLoS One. 2025 May 19;20(5):e0320903. doi: 10.1371/journal.pone.0320903. eCollection 2025. PLoS One. 2025. PMID: 40388525 Free PMC article.
References
-
- Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127–1131. - PubMed
-
- Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175–1186. - PubMed
-
- Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S, Asaka M. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372:392–397. - PubMed
-
- Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012;61:646–664. - PubMed
-
- Fock KM, Talley N, Moayyedi P, Hunt R, Azuma T, Sugano K, Xiao SD, Lam SK, Goh KL, Chiba T, et al. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol. 2008;23:351–365. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical